−0.68 USD
−41.57 M USD
152.58 M USD
21.73 M
About BillionToOne, Inc.
Sector
Industry
CEO
Atay Oguzhan
Website
Headquarters
Menlo Park
ISIN
US0901681058
FIGI
BBG00NR7JXT0
BillionToOne, Inc. develops DNA molecular counting technology. It can detect disorders such as sickle cell disease and cystic fibrosis. The company was founded by Oguzhan Atay, Sukrit Silas, and David Tsao and is headquartered in Palo Alto, CA.
Related stocks
Frequently Asked Questions
The current price of BLLN is 101.80 USD — it has increased by 2.40% in the past 24 hours. Watch BillionToOne, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange BillionToOne, Inc. stocks are traded under the ticker BLLN.
BLLN stock has risen by 6.25% compared to the previous week, the month change is a 6.25% rise, over the last year BillionToOne, Inc. has showed a 1.80% increase.
Yes, you can track BillionToOne, Inc. financials in yearly and quarterly reports right on TradingView.
BLLN net income for the last quarter is −246.00 K USD, while the quarter before that showed −3.99 M USD of net income which accounts for 93.83% change. Track more BillionToOne, Inc. financial stats to get the full picture.
No, BLLN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BillionToOne, Inc. EBITDA is −21.12 M USD, and current EBITDA margin is −23.24%. See more stats in BillionToOne, Inc. financial statements.
Like other stocks, BLLN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BillionToOne, Inc. stock right from TradingView charts — choose your broker and connect to your account.